Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Cipla: Eyeing the biotech market - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Sep 5, 2001

    Cipla: Eyeing the biotech market

    Cipla declared a 21% growth in revenues for the first five months ended Augustí01 at its AGM held on 4th September'01. Considering 1QFY02 figures, where revenues grew by 20% (gross), the first five months numbers reflect a better performance in two months viz July & Augustí01, especially when the industry as a whole is showing a decelerating growth. Few more details of the AGM as under.

    • Contingent liabilities, not a cause of concern now
      In a major development, the division bench of the Mumbai High court held that seven important bulk drugs (viz. Ciprofloxacin, norfloxacin, salbutamol, theophylline, cloxacillin, doxycycline, and glipizide) do not fall under the purview of the price control and that the DPCO is not applicable to them. This court case pertained to the governmentís view that Cipla (and other companies) had charged higher prices for 8 drugs, which were under the price control. However, the company had contended that the same were not liable to be included within the ambit of price control parameters laid down by the Drug policy. The total amount in question was to the tune of Rs 2.1 bn and the company had not created any provision for the same in its books. The court ruling in favour of the company came as a major relief to the shareholders as these contingent liabilities are unlikely to be a cause of concern for Cipla now.

    • R&D Front
      The company reiterated that it working on few molecules for NDDS (New Drug Delivery System). Besides, the company is also working on NCE (New chemical Entity). Cipla allocates around 4% of its sales revenue for its R&D programmes.

    • Foray into Biotech & Genetic Engineering
      The Company informed that it is interested in to venturing into biotech and Genetic engineering with a suitable foreign partner. Cipla is evaluating options for such possible tie-ups.

    • First Five-month results
      The sales for the first five months for the period ended Augustí01 has shown an overall increase of over 21% (gross) compared to the previous year. Exports have grown 75% in the five months period.

      We maintain our 32% revenue growth estimate for FY02 on the back of expected spurt in generic exports. Exports are expected to leapfrog in the second half of the current year as the company starts exports of Omeprazole and CFC inhalers to the European markets.

      At the current market price of Rs 1,231, the stock trades at 28x our expected earnings for FY02.

    • Read more on Cipla



    Equitymaster requests your view! Post a comment on "Cipla: Eyeing the biotech market". Click here!


    More Views on News

    Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

    Mar 8, 2017

    Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

    Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

    Sep 19, 2016

    Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 22, 2017 11:10 AM



    Compare Company With Charts